RCP

Remedium Capital Partners Portfolio holdings

AUM $170M
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
–
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$170M
AUM Growth
–
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
6
New
Increased
Reduced
Closed

Top Buys

1
+$43.3M
2
+$38.1M
3
+$36.8M
4
JBIO
Jade Biosciences
JBIO
+$18.5M
5
CBIO
Crescent Biopharma
CBIO
+$4.6M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
1
Spyre Therapeutics
SYRE
$3.28B
$47.7M 28.03%
+1,456,231
ORKA
2
Oruka Therapeutics
ORKA
$1.65B
$47.1M 27.64%
+1,552,414
APGE icon
3
Apogee Therapeutics
APGE
$4.67B
$44M 25.88%
+583,591
JBIO
4
Jade Biosciences
JBIO
$707M
$24.3M 14.3%
+1,577,750
CBIO
5
Crescent Biopharma
CBIO
$377M
$4.28M 2.52%
+361,250
GLTO icon
6
Galecto
GLTO
$1.86B
$2.77M 1.63%
+120,473